Neogenomics (NEO) Equity Average (2011 - 2026)

Neogenomics has reported Equity Average for 16 years, with the latest figure at $832.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 7.0% year-over-year to $832.7 million; the trailing twelve-month figure through Mar 2026 stood at $832.7 million (down 7.0% YoY), and the FY2025 full-year result was $869.5 million, down 5.69% from the prior year.
• Equity Average for Q1 2026 stood at $832.7 million, down from $837.4 million in the prior quarter.
• The five-year high for Equity Average was $1.1 billion in Q1 2022, with the low at $832.7 million in Q1 2026.
• Historically, Equity Average has averaged $940.3 million across 5 years, with a median of $932.5 million in 2024.
• The largest YoY upside for Equity Average was 41.96% in 2022 against a maximum downside of 10.44% in 2022.
• Neogenomics' Equity Average stood at $1.0 billion in 2022, then decreased by 6.07% to $944.5 million in 2023, then fell by 4.15% to $905.3 million in 2024, then fell by 7.49% to $837.4 million in 2025, then declined by 0.57% to $832.7 million in 2026.
• The last three Equity Average figures came in at $832.7 million (Q1 2026), $837.4 million (Q4 2025), and $846.2 million (Q3 2025), per Business Quant data.